SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway

Prostate cancer (PCa) remains the most common urological malignancy and the second leading cause of male cancer-related deaths in many developed countries (Siegel et al, 2016). Although the improvements in PCa diagnostic strategies and in multiple treatments have led to a significant decrease in PCa-related deaths in the past three decades, most men initially diagnosed with early-stage cancer eventually develop metastatic disease (Gundem et al, 2015). Thus, at this point, it remains practically incurable, and the aims of therapy are the improvement of overall survival time and quality of life. It is important to develop novel therapeutic strategies in order to suppress tumour progression and restore sensitivity to therapy.